Boom Times For Autoimmune Disease Therapies
In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push,…
SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of…